Biotech Financing
CNS Pharmaceuticals Secures Oversubscribed $22.5 Million Financing to Fuel Growth Strategy
CNS Pharmaceuticals highlights its oversubscribed $22.5 million financing and strategic reset in a virtual investor presentation, positioning the company to pursue transformational opportunities and create shareholder value.
Annovis Bio Announces Public Offering to Fund Buntanetap Alzheimer's Trial
Annovis Bio has proposed a public offering of common stock and warrants to raise capital for its Phase 3 Alzheimer's study and general corporate purposes.
Annovis Bio Raises $15 Million in Public Offering to Fund Neurodegenerative Disease Trials
Annovis Bio has priced a $15 million public offering of common stock and warrants, with proceeds earmarked for clinical development of its lead candidate buntanetap for Alzheimer's and Parkinson's diseases.
CNS Pharmaceuticals Raises $22.5 Million to Advance Pipeline and Corporate Strategy
CNS Pharmaceuticals announced a $22.5 million private placement with institutional investors to fund asset acquisition and working capital, signaling a strategic push to expand its pipeline.
ARMR Sciences Advances Fentanyl Vaccine Toward Human Trials with Private Placement
ARMR Sciences Inc. completed a private placement financing led by Joseph Gunnar & Co. to advance its preventive fentanyl vaccine toward human trials, aiming to address the synthetic drug crisis.
Cybin Secures $175 Million in Registered Direct Offering to Advance Mental Health Treatments
Cybin Inc. has raised $175 million through a registered direct offering, providing crucial funding to advance its late-stage clinical trials for novel mental health treatments including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.
Clene Inc. Advances Toward NDA Submission for ALS Treatment CNM-Au8, Extends Financial Runway
Clene Inc. is preparing to submit a New Drug Application for its ALS treatment candidate CNM-Au8 by year-end 2025 while securing financial stability through recent financing that extends its cash runway into early 2026.
Quantum BioPharma Ltd. Announces $600 Private Placement to Support Working Capital
Quantum BioPharma Ltd. (NASDAQ: QNTM) has launched a $600 private placement of Class A Multiple Voting Shares to bolster its working capital, highlighting the company's strategic financial planning amidst its focus on innovative biotech solutions.